Dendreon was the worst-performing stock, as its note that sales of its prostate cancer treatment Provenge would be lower than expected led shares to crater 67%.
The same will happen to FB stock. (Note: Silverline is down 98% from 2007 launch.) Remember the hype surrounding Reliance Power (BOM: 532939)? (Note: Reliance Power down more than 60% since IPO.) Brokers brayed and pushed the retail investor to invest and what happened was the retail people lost.
Note that stock based compensation and corporate expense are not allocated to the geographies or retail so that the numbers do not add up (as you can see by the companies total operating margin declining 620 basis points in the fiscal third quarter but all of the geos are less than that).